Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.4
3.1
Journals
CIMB
Special Issues
Molecular Genetics and Genomics in Neurodegenerative Diseases
cimb-logo
Submit to CIMB Review for CIMB Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Genetics and Genomics in Neurodegenerative Diseases

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 4127

Special Issue Editor

Dr. Weiran Shan

E-Mail Website
Guest Editor
Department of Anesthesiology, University of Virginia, Charlottesville, VA 22901, USA
Interests: neurodegenerative disease; cognitive function; brain ischemia; behavior study

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases are characterized by the progressive loss of structure or function of neurons, glial cells, and the neural networks in the brain and spinal cord, affecting people’s movement, mental functioning, speech and breath. Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases. With the efforts of many researchers, some patho-mechanisms underlying these diseases have been proposed, such as genetic mutations, neuroinflammation, mitochondria dysfunction, redox imbalance, and autophagy dysfunction. During the past few decades, remarkable advances has been witnessed in gene sequencing technology. Genome-wide association studies (GWASs) have been applied to identify susceptibility genes and risk variants. The rapid development of bioinformatic technology and the reduced cost of gene sequencing enables the advances in next-generation gene sequencing (NGS). Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are now widely applied in identifying rare variant genes, as well as casual and susceptibility genes in neurodegenerative diseases. The advanced technology has enabled us to identify potential therapeutic interventions for diagnosis or control of neurodegeneration.

The scope of this Special Issue is mainly focused on basic and clinical studies. We would like to invite you submit both original contributions and review articles related to the recent advances in genetic research related to the diagnosis, pathophysiology, and treatment of neurodegenerative diseases.

Dr. Weiran Shan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genetics
  • genes
  • bioinformatics
  • neurodegenerative disease
  • dementia
  • Alzheimer’s disease
  • Parkinson’s disease
  • Huntington’s disease
  • Lewy body dementia
  • amyotrophic lateral sclerosis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 460 KiB  
Article
Genetic Predisposition for White Matter Hyperintensities and Risk of Mild Cognitive Impairment and Alzheimer’s Disease: Results from the HELIAD Study
by Stefanos N. Sampatakakis, Niki Mourtzi, Sokratis Charisis, Eirini Mamalaki, Eva Ntanasi, Alexandros Hatzimanolis, Alfredo Ramirez, Jean-Charles Lambert, Mary Yannakoulia, Mary H. Kosmidis, Efthimios Dardiotis, Georgios Hadjigeorgiou, Paraskevi Sakka and Nikolaos Scarmeas
Curr. Issues Mol. Biol. 2024, 46(1), 934-947; https://doi.org/10.3390/cimb46010060 - 22 Jan 2024
Viewed by 1005
Abstract
The present study investigated the association of genetic predisposition for white matter hyperintensities (WMHs) with incident amnestic mild cognitive impairment (aMCI) or Alzheimer’s disease (AD), as well as whether such an association was influenced by age, sex, and cognitive reserve. Overall, 537 individuals [...] Read more.
The present study investigated the association of genetic predisposition for white matter hyperintensities (WMHs) with incident amnestic mild cognitive impairment (aMCI) or Alzheimer’s disease (AD), as well as whether such an association was influenced by age, sex, and cognitive reserve. Overall, 537 individuals without aMCI or dementia at baseline were included. Among them, 62 individuals developed aMCI/AD at follow up. Genetic propensity to WMH was estimated using a polygenic risk score for WMHs (PRS WMH). The association of PRS WMH with aMCI/AD incidence was examined using COX models. A higher PRS WMH was associated with a 47.2% higher aMCI/AD incidence (p = 0.015) in the fully adjusted model. Subgroup analyses showed significant results in the older age group, in which individuals with a higher genetic predisposition for WMHs had a 3.4-fold higher risk for developing aMCI/AD at follow up (p < 0.001), as well as in the lower cognitive reserve (CR, proxied by education years) group, in which individuals with a higher genetic predisposition for WMHs had an over 2-fold higher risk (p = 0.013). Genetic predisposition for WMHs was associated with aMCI/AD incidence, particularly in the group of participants with a low CR. Thus, CR might be a modifier in the relationship between genetic predisposition for WMHs and incident aMCI/AD. Full article
(This article belongs to the Special Issue Molecular Genetics and Genomics in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

18 pages, 5257 KiB  
Article
Machine Learning Analysis of Alzheimer’s Disease Single-Cell RNA-Sequencing Data across Cortex and Hippocampus Regions
by Marios G. Krokidis, Aristidis G. Vrahatis, Konstantinos Lazaros, Konstantina Skolariki, Themis P. Exarchos and Panagiotis Vlamos
Curr. Issues Mol. Biol. 2023, 45(11), 8652-8669; https://doi.org/10.3390/cimb45110544 - 28 Oct 2023
Cited by 1 | Viewed by 1195
Abstract
Advancements in molecular biology have revolutionized our understanding of complex diseases, with Alzheimer’s disease being a prime example. Single-cell sequencing, currently the most suitable technology, facilitates profoundly detailed disease analysis at the cellular level. Prior research has established that the pathology of Alzheimer’s [...] Read more.
Advancements in molecular biology have revolutionized our understanding of complex diseases, with Alzheimer’s disease being a prime example. Single-cell sequencing, currently the most suitable technology, facilitates profoundly detailed disease analysis at the cellular level. Prior research has established that the pathology of Alzheimer’s disease varies across different brain regions and cell types. In parallel, only machine learning has the capacity to address the myriad challenges presented by such studies, where the integration of large-scale data and numerous experiments is required to extract meaningful knowledge. Our methodology utilizes single-cell RNA sequencing data from healthy and Alzheimer’s disease (AD) samples, focused on the cortex and hippocampus regions in mice. We designed three distinct case studies and implemented an ensemble feature selection approach through machine learning, also performing an analysis of distinct age-related datasets to unravel age-specific effects, showing differential gene expression patterns within each condition. Important evidence was reported, such as enrichment in central nervous system development and regulation of oligodendrocyte differentiation between the hippocampus and cortex of 6-month-old AD mice as well as regulation of epinephrine secretion and dendritic spine morphogenesis in 15-month-old AD mice. Our outcomes from all three of our case studies illustrate the capacity of machine learning strategies when applied to single-cell data, revealing critical insights into Alzheimer’s disease. Full article
(This article belongs to the Special Issue Molecular Genetics and Genomics in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

15 pages, 4102 KiB  
Article
Mixed Medicinal Mushroom Mycelia Attenuates Alzheimer’s Disease Pathologies In Vitro and In Vivo
by Ji Heun Jeong, Geum-Lan Hong, Young Gil Jeong, Nam Seob Lee, Do Kyung Kim, Jong Yea Park, Mina Park, Hyun Min Kim, Ya El Kim, Yung Choon Yoo and Seung Yun Han
Curr. Issues Mol. Biol. 2023, 45(8), 6775-6789; https://doi.org/10.3390/cimb45080428 - 15 Aug 2023
Viewed by 1364
Abstract
Alzheimer’s disease (AD) is characterized by memory impairment and existence of amyloid-β (Aβ) plaques and neuroinflammation. Due to the pivotal role of oxidative damage in AD, natural antioxidative agents, such as polyphenol-rich fungi, have garnered scientific scrutiny. Here, the aqueous extract of mixed [...] Read more.
Alzheimer’s disease (AD) is characterized by memory impairment and existence of amyloid-β (Aβ) plaques and neuroinflammation. Due to the pivotal role of oxidative damage in AD, natural antioxidative agents, such as polyphenol-rich fungi, have garnered scientific scrutiny. Here, the aqueous extract of mixed medicinal mushroom mycelia (MMMM)—Phellinus linteus, Ganoderma lucidum, and Inonotus obliquus—cultivated on a barley medium was assessed for its anti-AD effects. Neuron-like PC12 cells, which were subjected to Zn2+, an Aβ aggregator, were employed as an in vitro AD model. The cells pretreated with or without MMMM were assayed for Aβ immunofluorescence, cell viability, reactive oxygen species (ROS), apoptosis, and antioxidant enzyme activity. Then, 5XFAD mice were administered with 30 mg/kg/day MMMM for 8 weeks and underwent memory function tests and histologic analyses. In vitro results demonstrated that the cells pretreated with MMMM exhibited attenuation in Aβ immunofluorescence, ROS accumulation, and apoptosis, and incrementation in cell viability and antioxidant enzyme activity. In vivo results revealed that 5XFAD mice administered with MMMM showed attenuation in memory impairment and histologic deterioration such as Aβ plaque accumulation and neuroinflammation. MMMM might mitigate AD-associated memory impairment and cerebral pathologies, including Aβ plaque accumulation and neuroinflammation, by impeding Aβ-induced neurotoxicity. Full article
(This article belongs to the Special Issue Molecular Genetics and Genomics in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop